Roivant Sciences (ROIV) Selling, General & Administrative (2020 - 2026)
Powered by 
Analysis
Roivant Sciences (ROIV) Selling, General & Administrative (2020 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | SG&A (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 212.13 Bn | 198.14 Bn | 7.24 Bn | 1.75 Bn |
| 2 | Gilead Sciences | 181.95 Bn | 178.77 Bn | 6.22 Bn | 1.92 Bn |
| 3 | Vertex Pharmaceuticals | 132.50 Bn | 124.65 Bn | 2.84 Bn | 582.20 Mn |
| 4 | Regeneron Pharmaceuticals | 82.67 Bn | 74.68 Bn | 3.93 Bn | 662.10 Mn |
| 5 | Argenx Se | 61.55 Bn | 56.37 Bn | 1.37 Bn | -417.00 Mn |
| 6 | Moderna | 54.65 Bn | 49.51 Bn | 52.00 Mn | 216.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.23 Bn | 30.92 Bn | 992.69 Mn | 347.92 Mn |
| 8 | Biogen | 31.46 Bn | 30.18 Bn | 1.96 Bn | 709.70 Mn |
| 9 | Roivant Sciences | 30.19 Bn | 30.19 Bn | 1.16 Mn | 165.53 Mn |
| 10 | Insmed | 27.89 Bn | 26.72 Bn | 358.27 Mn | 247.47 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 165.53 Mn |
| Dec 31, 2025 | 452.22 Mn |
| Sep 30, 2025 | 143.13 Mn |
| Jun 30, 2025 | 134.02 Mn |
| Dec 31, 2024 | 444.32 Mn |
| Sep 30, 2024 | 202.88 Mn |
| Jun 30, 2024 | 99.89 Mn |
| Dec 31, 2023 | 308.03 Mn |
| Sep 30, 2023 | 88.58 Mn |
| Jun 30, 2023 | 156.19 Mn |
| Dec 31, 2022 | 475.00 Mn |
| Sep 30, 2022 | 157.66 Mn |
| Jun 30, 2022 | 149.07 Mn |
| Dec 31, 2021 | 636.06 Mn |
| Sep 30, 2021 | 437.78 Mn |
| Jun 30, 2021 | 82.75 Mn |
| Dec 31, 2020 | 61.88 Mn |
| Sep 30, 2020 | 59.74 Mn |
| Jun 30, 2020 | 57.12 Mn |